Article thumbnail
Location of Repository

Cell entry and exit of porcine endogenous retrovirus A: receptors and release inhibitor

By G. Mattiuzzo

Abstract

Following the discovery that porcine endogenous retrovirus (PERV) can infect human cells, the potential risk of a zoonotic infection by PERV has been a major obstacle in the xenotransplantation field. The aim of this thesis is to gain a better understanding of PERV biology, so as to help assess and reduce the risk of PERV zoonosis. PERV subgroup A can enter human cells through two human PERV-A receptors (huPAR-1 and -2). To determine critical regions in the receptor for PERV-A infection, chimeric receptors between huPAR-2 and the non functional murine PAR (muPAR) have been analysed. A single amino acid difference (amino acid 109) was found responsible for the inability of muPAR to mediate PERV-A binding and infection. These results were then applied to the evaluation of PERV infection of non-human primates (NHP). NHP could represent an ideal animal model for assessing the risk of zoonosis following long-term exposure to porcine material. However, PERV does not infect NHP cells with the same efficiency as it does human cells. The data presented in this thesis suggests that in some NHP species the poor infectivity is due to mutation of the same critical amino acid (a.a.109) described for muPAR. However, African green monkey cells express two functional receptors and other mechanisms are likely to be responsible for the low susceptibility to PERV-A infection. Secondly, I evaluated the effect of a release inhibitor as a possible strategy to reduce PERV dissemination from pig cells. Human tetherin can inhibit retrovirus production from cells. I showed that overexpression of human and newly cloned porcine tetherin in pig cells can reduce the release of PERV. My data suggests that tetherin-expressing transgenic pigs could represent a safer donor in xenotransplantation

Publisher: UCL (University College London)
Year: 2010
OAI identifier: oai:eprints.ucl.ac.uk.OAI2:19218
Provided by: UCL Discovery

Suggested articles

Citations

  1. (2007). [Autochthonous hepatitis E in France and consumption of raw pig meat].
  2. (2003). 222 Identification of receptors for pig endogenous retrovirus.
  3. (2007). 228 Person-to-person transmission of Nipah virus in a Bangladeshi community.
  4. (2008). 251 Differential human serum-mediated neutralization of PERV released from pig cells transfected with variants of hDAF.
  5. (2003). 254 Production of alpha 1,3-galactosyltransferase-deficient pigs.
  6. 3rd (2001). Targeting histone deacetylase complexes via KRAB-zinc finger proteins: the PHD and bromodomains of KAP-1 form a cooperative unit that recruits a novel isoform of the Mi-2alpha subunit of NuRD.
  7. 3rd (2002). SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins.
  8. (2009). A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells.
  9. (2000). A century of typhus, lice and Rickettsia.
  10. (2000). A conserved mechanism of retrovirus restriction in mammals.
  11. (1994). A critical site in the cell surface receptor for ecotropic murine retroviruses required for amino acid transport but not for viral reception.
  12. (2002). A dominant block to HIV-1 replication at reverse transcription in simian cells.
  13. (1994). A family of retroviruses that utilize related phosphate transporters for cell entry.
  14. (1994). A human amphotropic retrovirus receptor is a second member of the gibbon ape leukemia virus receptor family.
  15. (1999). A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction.
  16. (1997). A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes.
  17. (1971). A major genetic locus affecting resistance to infection with murine leukemia viruses. II. Apparent identity to a major locus described for resistance to friend murine leukemia virus.
  18. (1984). A Mus dunni cell line that lacks sequences closely related to endogenous murine leukemia viruses and can be infected by ectropic, amphotropic, xenotropic, and mink cell focusforming viruses.
  19. (2008). A new arenavirus in a cluster of fatal transplant-associated diseases.
  20. (1996). A new variant of Creutzfeldt-Jakob disease in the UK.
  21. (2007). A novel fusion gene, TRIM5-Cyclophilin A in the pig-tailed macaque determines its susceptibility to HIV-1 infection.
  22. (1988). A novel gene of HIV-1, vpu, and its 16-kilodalton product.
  23. (1998). A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif.
  24. (1995). A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.
  25. (1994). A novel membrane antigen selectively expressed on terminally differentiated human B cells.
  26. (2006). A novel strategy for preventing PERV transmission to human cells by remodeling the viral envelope glycoprotein.
  27. (1997). A novel virus in swine is closely related to the human hepatitis E virus.
  28. (1992). A novel zinc finger coiled-coil domain in a family of nuclear proteins.
  29. (2008). A placenta-specific receptor for the fusogenic, endogenous retrovirus-derived, human syncytin-2.
  30. (2000). A polymerase chain reaction-based protocol for the detection of transmission of pig endogenous retroviruses in pig to human xenotransplantation.
  31. (1996). A possible involvement of TIF1 alpha and TIF1 beta in the epigenetic control of transcription by nuclear receptors.
  32. (1998). A proline-rich motif downstream of the receptor binding domain modulates conformation and fusogenicity of murine retroviral envelopes.
  33. (1999). A putative cell surface receptor for anemia-inducing feline leukemia virus subgroup C is a member of a transporter superfamily.
  34. (1989). A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection.
  35. (2006). A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A.
  36. (2006). A recombinant endogenous retrovirus amplified in a mouse neuroblastoma is involved in tumor growth in vivo.
  37. (2005). A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction.
  38. (2004). A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
  39. (2004). A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
  40. (2004). A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
  41. (2004). A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factorinduced depletion.
  42. (1994). A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent.
  43. (1999). A sodium-dependent neutral-amino-acid transporter mediates infections of feline and baboon endogenous retroviruses and simian type D retroviruses.
  44. (2005). A specific region of 37 amino acid residues in the SPRY (B30.2) domain of African green monkey TRIM5alpha determines species-specific restriction of simian immunodeficiency virus SIVmac infection.
  45. (1991). A stem cell-specific silencer in the primer-binding site of a retrovirus.
  46. (1997). A structured retroviral RNA element that mediates nucleocytoplasmic export of intron-containing RNA.
  47. (1995). A transient three-plasmid expression system for the production of high titer retroviral vectors.
  48. (2008). A transitional endogenous lentivirus from the genome of a basal primate and implications for lentivirus evolution.
  49. (2001). A unique heparin-binding domain in the envelope protein of the neuropathogenic PVC-211 murine leukemia virus may contribute to its brain capillary endothelial cell tropism.
  50. (1978). Abrogation of Fv-1b restriction with murine leukemia viruses inactivated by heat or by gamma irradiation.
  51. (2002). Abrogation of Ref1 retrovirus restriction in human cells.
  52. (2005). Absence of PERV infection in baboons after transgenic porcine liver perfusion.
  53. (2008). Absence of replication of porcine endogenous retrovirus and porcine lymphotropic herpesvirus type 1 with 232 prolonged pig cell microchimerism after pig-to-baboon xenotransplantation.
  54. (2004). Absence of replication-competent human-tropic porcine endogenous retroviruses in the germ line DNA of inbred miniature Swine.
  55. (2000). Activation of a cell entry pathway common to type C mammalian retroviruses by soluble envelope fragments.
  56. (2001). Activation of membrane fusion by murine leukemia viruses is controlled in cis or in trans by interactions between the receptor-binding domain and a conserved disulfide loop of the carboxy terminus of the surface glycoprotein.
  57. (1982). Activation of SV40 genome by 72-base pair tandem repeats of Moloney sarcoma virus.
  58. (1992). Active nuclear import of human immunodeficiency virus type 1 preintegration complexes.
  59. (2005). alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months.
  60. (1991). Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly.
  61. (1991). An amino-terminal fragment of the Friend murine leukemia virus envelope glycoprotein binds the ecotropic receptor.
  62. (2002). An anthropoid-specific locus of orphan C to U RNAediting enzymes on chromosome 22.
  63. (2000). An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor.
  64. (2007). An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.
  65. (2007). An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.
  66. (1995). An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors.
  67. (2000). An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells.
  68. (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system.
  69. (2001). Analysis of patients treated with living pig tissue for evidence of infection by porcine endogenous retroviruses.
  70. (2000). Analysis of potential porcine endogenous retrovirus transmission to baboon in vitro and in vivo.
  71. and Clustal X version 2.0.
  72. (1979). Anti-Friend virus antibody is associated with recovery from viremia and loss of viral leukemia cell-surface antigens in leukemic mice. Identification of Rfv-3 as a gene locus influencing antibody production.
  73. (1995). Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes.
  74. (2009). Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.
  75. (1994). Antigenic and sequence analysis of H3 influenza virus haemagglutinins from pigs in Italy.
  76. (1996). Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein.
  77. (2000). Antiretroviral agents inhibit infection of human cells by porcine endogenous retroviruses.
  78. (1998). Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.
  79. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
  80. (2008). APOBEC3 proteins and porcine endogenous retroviruses.
  81. (2004). APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
  82. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
  83. (2005). APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.
  84. (1981). Avian leukosis virus-induced tumors have common proviral 249 integration sites and synthesize discrete new RNAs: oncogenesis by promoter insertion.
  85. (1979). Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses.
  86. (1996). Avian retroviral RNA element promotes unspliced RNA accumulation in the cytoplasm.
  87. (1975). Biologic and immunologic properties of porcine type C viruses.
  88. (2003). Body language: the function of PML nuclear bodies in apoptosis regulation.
  89. (2006). Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation.
  90. (1994). Brief report: treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation.
  91. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
  92. (2009). Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.
  93. (2003). Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.
  94. (1971). C-type virus particles in pig kidney cell lines.
  95. (2000). Casecontrol study of risk factors for human infection with a new zoonotic paramyxovirus, Nipah virus, during a 1998-1999 outbreak of severe encephalitis in Malaysia.
  96. (2002). Cell communication.
  97. (2003). Cell surface receptors for gammaretroviruses.
  98. (1994). Cell type-dependence for Vpu function.
  99. (2005). Cell-binding properties of the envelope proteins of porcine endogenous retroviruses.
  100. (1994). Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters.
  101. (2000). Cellular and species resistance to murine amphotropic, gibbon ape, and feline subgroup C leukemia viruses is strongly influenced by receptor expression levels and by receptor masking mechanisms.
  102. (2007). Changes in viral protein function that accompany retroviral endogenization.
  103. (1990). Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus.
  104. (1985). Characterization of a molecularly cloned retroviral sequence associated with Fv-4 resistance.
  105. (2005). Characterization of a monoclonal antibody specific to the Gag protein of 214 porcine endogenous retrovirus and its application in detecting the virus infection.
  106. (2002). Characterization of a novel simian immunodeficiency virus with a vpu gene from greater spot-nosed monkeys (Cercopithecus nictitans) provides new insights into simian/human immunodeficiency virus phylogeny.
  107. (2002). Characterization of a polytropic murine leukemia virus proviral sequence associated with the virus resistance gene Rmcf of DBA/2 mice.
  108. (1974). Characterization of a type C virus released from the porcine cell line PK(15).
  109. (2000). Characterization of an internal ribosomal entry segment in the 5' leader of murine leukemia virus env RNA.
  110. (1997). Characterization of an internal ribosomal entry segment within the 5' leader of avian reticuloendotheliosis virus type A RNA and development of novel MLV-REVbased retroviral vectors.
  111. (2002). Characterization of chromosomally assigned replication-competent gamma porcine endogenous retroviruses derived from a large white pig and expression in human cells.
  112. (1984). Characterization of enhancer elements in the long terminal repeat of Moloney murine sarcoma virus.
  113. (2002). Characterization of Moloney murine leukemia virus p12 mutants blocked during early events of infection.
  114. (1998). Characterization of the proline-rich region of murine leukemia virus envelope protein.
  115. (2006). Chimpanzee reservoirs of pandemic and nonpandemic HIV-1.
  116. (1986). Chromosomal position or virus mutation permits retrovirus expression in embryonal carcinoma cells.
  117. (2001). cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor.
  118. (1997). Clinical xenotransplantation: past, present and future.
  119. (1999). Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses.
  120. (2007). Cloning and functional characterization of a gammahydroxybutyrate receptor identified in the human brain.
  121. (1997). Cloning of a new murine endogenous retrovirus, MuERV-L, with strong similarity to the human HERV-L element and with a gag coding sequence closely related to the Fv1 restriction gene.
  122. (1994). Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus.
  123. (2000). Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia.
  124. (1996). Cloning of the sodium-235 dependent, broad-scope, neutral amino acid transporter Bo from a human placental choriocarcinoma cell line.
  125. (1996). Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine.
  126. (1999). Construction of a swine BAC library: application to the characterization and mapping of porcine type C endoviral elements.
  127. (1994). Continuous propagation of RRE(-) and Rev(-)RRE(-) human immunodeficiency virus type 1 molecular clones containing a cis-acting element of simian retrovirus type 1 in human peripheral blood lymphocytes.
  128. (1999). cORF and RcRE, the Rev/Rex and RRE/RxRE homologues of the human endogenous retrovirus family HTDV/HERV-K.
  129. Correlation with antinuclear antibodies and HLA class II alleles.
  130. (2007). Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).
  131. (2004). Cytoplasmic PML function in TGF-beta signalling.
  132. (2001). Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication.
  133. (1998). Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1.
  134. (2001). DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans.
  135. (2007). Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.
  136. (1994). Defective endogenous proviruses are expressed in feline lymphoid cells: evidence for a role in natural resistance to subgroup B feline leukemia viruses.
  137. (1993). Definition of a domain of GLVR1 which is necessary for infection by gibbon ape leukemia virus and which is highly polymorphic between species.
  138. (1988). Dengue. In Epidemiology of arthropod-borne viral
  139. (2000). Design and validation of immunological tests for the detection of Porcine endogenous retrovirus in biological materials.
  140. (2007). Detection of a neonatal human rotavirus strain with VP4 and NSP4 genes of porcine origin.
  141. (2003). Detection of porcine endogenous retrovirus (PERV) using highly specific antisera against Gag and Env.
  142. (2004). Determinant for the inhibition of ecotropic murine leukemia virus infection by N-linked glycosylation of the rat receptor.
  143. (2004). Determinants of high titer in recombinant porcine endogenous retroviruses.
  144. (1991). Determinants of retrovirus gene expression in embryonal carcinoma cells.
  145. (1999). Development and validation of a Western 244 immunoblot assay for detection of antibodies to porcine endogenous retrovirus.
  146. (1991). Development of a whole killed feline leukemia virus vaccine.
  147. (1996). Development of mucosal and systemic lymphoproliferative responses and 270 protective immunity to human group A rotaviruses in a gnotobiotic pig model.
  148. (1985). Different murine cell lines manifest unique patterns of interference to superinfection by murine leukemia viruses.
  149. (1984). Different recombinant murine leukemia viruses use different cell surface receptors.
  150. (2007). Differential resistance to cell entry by porcine endogenous retrovirus subgroup A in rodent species.
  151. (2005). Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.
  152. (2007). Discovery and analysis of the first endogenous lentivirus.
  153. (2009). Discovery of swine as a host for the Reston ebolavirus.
  154. (2009). Distribution and expression of porcine endogenous retroviruses in multi-transgenic pigs generated for xenotransplantation.
  155. (2003). DNA deamination mediates innate immunity to retroviral infection.
  156. (2003). Do lipid rafts mediate virus assembly and pseudotyping?
  157. (2005). Early weaning of piglets fails to exclude porcine lymphotropic herpesvirus.
  158. (2007). Ecotropic murine leukemia virus envelope protein affects interaction of cationic amino acid transporter 1 with clathrin adaptor protein complexes, leading to receptor downregulation.
  159. (1976). Effect of Fv-1 gene product on proviral DNA formation and integration in cells infected with murine leukemia viruses.
  160. (1992). Effects of ecotropic murine retroviruses on the dual-function cell surface receptor/basic amino acid transporter.
  161. (2003). Efficacy of a canarypox virus-vectored vaccine against feline leukaemia.
  162. (1991). Efficient selection for highexpression transfectants with a novel eukaryotic vector.
  163. (2009). Embryonic stem cells use ZFP809 to silence retroviral DNAs.
  164. (2008). Endogenous retroviruses and cancer.
  165. (1997). Endogenous retroviruses and the evolution of resistance to retroviral infection.
  166. (2006). Endogenous retroviruses regulate periimplantation placental growth and differentiation.
  167. (1997). Enhancement of retroviral production from packaging cell lines expressing the human immunodeficiency type 1 VPU gene.
  168. (1998). Entry of amphotropic murine leukemia virus is influenced by residues in the putative second extracellular domain of its receptor,
  169. (1993). Envelope-binding domain in the cationic amino acid transporter determines the host range of ecotropic murine retroviruses.
  170. (1993). Equine retroviruses.
  171. (2000). Establishment and characterization of molecular clones of porcine endogenous retroviruses replicating on human cells.
  172. (1995). European swine virus as a possible source for the next influenza pandemic?
  173. (1991). Evaluation of a killed, whole virion feline leukemia virus vaccine.
  174. (1991). Evaluation of efficacy and safety of an inactivated virus vaccine against feline leukemia virus infection.
  175. (2004). Evidence and consequence of porcine endogenous retrovirus recombination.
  176. (1983). Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route.
  177. (2000). Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts.
  178. (2008). Evidence for zoonotic transmission of group C rotaviruses among children in Belem,
  179. (2008). Evolution of a TRIM5-CypA splice isoform in old world monkeys.
  180. (2007). Expression of porcine endogenous retroviruses (PERVs) in melanomas of Munich miniature swine (MMS)
  181. (2003). Expression of the zinc-finger antiviral protein inhibits alphavirus replication.
  182. (2000). Extended analysis of the in vitro tropism of porcine endogenous retrovirus.
  183. (2005). Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.
  184. (1999). Fatal encephalitis due to Nipah virus among pig-farmers in Malaysia.
  185. (2003). Feline leukaemia virus and vaccination.
  186. (1992). Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus.
  187. (2005). Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.
  188. (2003). Foamy virus envelope glycoprotein-mediated entry involves a pHdependent fusion process.
  189. (2006). Following the path of the virus: the exploitation of host DNA repair mechanisms by retroviruses.
  190. (1967). Foot-and-mouth disease in man.
  191. (2008). for hepatitis e virus infection in laboratory monkeys and pigs in animal facilities in Japan.
  192. (2008). Full genome-based classification of rotaviruses reveals a common origin between human Wa-Like and porcine rotavirus strains and human DS1-like and bovine rotavirus strains.
  193. (2005). Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.
  194. (2008). Functional hierarchy of two L domains in porcine endogenous retrovirus (PERV) that influence release and infectivity.
  195. (1988). Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein.
  196. (2005). G to A hypermutation of hepatitis B virus.
  197. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
  198. (2008). gene influencing neutralizing antibody control of retrovirus infection.
  199. (1998). Genetic and experimental evidence for cross-species infection by swine hepatitis E virus.
  200. (1997). Genetics of the rotaviruses.
  201. (2005). Genome-wide analysis of retroviral DNA integration.
  202. (2003). Genomewide screening for fusogenic human endogenous retrovirus envelopes identifies syncytin 2, a gene conserved on primate evolution.
  203. (2006). Genomic presence of recombinant porcine endogenous retrovirus in transmitting miniature swine.
  204. (1982). Glycosylation and intracellular transport of membrane glycoproteins encoded by murine leukemia viruses. Inhibition by amino acid analogues and by tunicamycin.
  205. (1994). Glycosylation-dependent inactivation of the ecotropic murine leukemia virus receptor.
  206. (2005). Heart transplantation in baboons using alpha1,3-galactosyltransferase geneknockout pigs as donors: initial experience.
  207. (2007). Hepatitis E associated with surgical training on pigs.
  208. (2007). Hepatitis E virus RNA in commercial porcine livers in The Netherlands.
  209. (2008). Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention.
  210. (2007). Hepatitis E virus.
  211. (1999). High throughput detection of retrovirus-associated reverse transcriptase using an improved fluorescent product enhanced reverse transcriptase assay and its comparison to conventional detection methods.
  212. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter.
  213. (1997). Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease.
  214. (2005). History of xenotransplantation.
  215. (2009). HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.
  216. (2002). HIV-1 integration in the human genome favors active genes and local hotspots.
  217. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
  218. (2006). HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.
  219. (1999). Host cyclophilin A mediates HIV-1 attachment to target cells via heparans.
  220. (1998). Host range and interference studies of three classes of pig endogenous retrovirus.
  221. (2008). Host restriction factors blocking retroviral replication.
  222. (1970). Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures.
  223. (1997). Hostderived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity.
  224. (2002). Human CD59 incorporation into porcine endogenous retrovirus particles: implications for the use of transgenic pigs for xenotransplantation.
  225. (1995). Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury.
  226. (2007). Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
  227. (2006). Human immunodeficiency virus type 1 Gag protein binds to cyclophilins A and B.
  228. (1996). Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.
  229. (2001). Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates.
  230. (2005). Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.
  231. (2003). Hybrid origin of SIV in chimpanzees.
  232. (2008). Hypermutation of an ancient human retrovirus by APOBEC3G.
  233. (2008). Identification and functional characterization of a novel human and rat riboflavin transporter, RFT1.
  234. (2000). Identification of a cellular cofactor required for infection by feline leukemia virus.
  235. (2009). Identification of a feline leukemia virus variant that can use THTR1, FLVCR1, and FLVCR2 for infection.
  236. (1998). Identification of a full-length cDNA for an endogenous retrovirus of miniature swine.
  237. (2004). Identification of a human heme exporter that is essential for erythropoiesis.
  238. (2003). Identification of a new simian immunodeficiency virus lineage with a vpu gene present among different cercopithecus monkeys
  239. (1979). Identification of a non-H-2 gene (Rfv-3) influencing recovery from viremia and leukemia induced by Friend virus complex.
  240. (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome.
  241. (1993). Identification of amino acid residues critical for infection with ecotropic murine leukemia retrovirus.
  242. (2004). Identification of an extracellular domain within the human PiT2 receptor that is required for amphotropic murine leukemia virus binding.
  243. (2004). Identification of exogenous forms of human-tropic porcine endogenous retrovirus in miniature Swine.
  244. (2001). Identification of novel porcine endogenous betaretrovirus sequences in miniature swine.
  245. (2008). Identification of the myelin protein plasmolipin as the cell entry receptor for Mus caroli endogenous retrovirus.
  246. (1992). Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus.
  247. (2009). Identification of two distinct structural regions in a human porcine endogenous retrovirus receptor, HuPAR2, contributing to function for viral entry.
  248. (2006). In vitro characterization of a koala retrovirus.
  249. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
  250. (2008). Independent evolution of an antiviral TRIMCyp in rhesus macaques.
  251. (1983). Independent mechanisms involved in suppression of the Moloney leukemia virus genome during differentiation of murine teratocarcinoma cells.
  252. (1985). Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III.
  253. Induction of APOBEC3G ubiquitination and degradation by an
  254. (1993). Induction of feline leukaemia virusneutralizing antibodies by immunization with synthetic peptides derived from the FeLV env gene.
  255. (2000). Infection by porcine endogenous retrovirus after islet xenotransplantation in SCID mice.
  256. (1997). Infection of human cells by an endogenous retrovirus of pigs.
  257. (2000). Infection of nonhuman primate cells by pig endogenous retrovirus.
  258. (2001). Infectious entry by amphotropic as well as ecotropic murine leukemia viruses occurs through an endocytic pathway.
  259. (1973). Influence of tumour growth on the evolution of cytotoxic lymphoid cells in rats bearing a spontaneously metastasizing syngeneic fibrosarcoma.
  260. (1969). Inheritance of Susceptibility to Friend Mouse Leukemia Virus: VI. Reciprocal Alteration of Innate Resistance or Susceptibility by Bone Marrow Transplantation Between Congenic Strains.
  261. (2004). Inhibition of different Lassa virus strains by alpha and gamma interferons and comparison with a less pathogenic arenavirus.
  262. (2002). Inhibition of endosomal/lysosomal degradation increases the infectivity of human immunodeficiency virus.
  263. (2007). Inhibition of filovirus replication by the zinc finger antiviral protein.
  264. Inhibition of Lassa and Marburg virus production by tetherin.
  265. (2007). Inhibition of porcine endogenous retroviruses (PERVs) in primary porcine cells by RNA interference using lentiviral vectors.
  266. (2004). Inhibition of porcine endogenous retroviruses by RNA interference: increasing the safety of xenotransplantation.
  267. (2002). Inhibition of retroviral RNA production by ZAP, a CCCH-type zinc finger protein.
  268. (1993). Inhibitors of retrovirus infection are secreted by several hamster cell lines and are also present in hamster sera.
  269. (1997). Initial genetic characterization of the 1918 "Spanish" influenza virus.
  270. (1988). Interaction between human natural anti-alpha-galactosyl 225 immunoglobulin G and bacteria of the human flora.
  271. (1982). Interference grouping of murine leukemia viruses: a distinct receptor for the MCF-recombinant viruses in mouse cells.
  272. (1995). Interspecies transmission of influenza viruses.
  273. (2003). Intracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses.
  274. (1997). Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution.
  275. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
  276. (1987). Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.
  277. (2002). Isolation of Nipah virus from Malaysian Island flying-foxes.
  278. (1994). Isolation of pseudorabies (Aujeszky's disease) virus from a Florida panther.
  279. (1976). Isolation of swine influenza virus from autopsy lung tissue of man.
  280. (1985). Isolation of T-cell tropic HTLV-III-like retrovirus from macaques.
  281. (2008). IXA Presidential Address. Progress toward an ideal source animal: opportunities and challenges in a changing world.
  282. (1996). KAP-1, a novel corepressor for the highly conserved KRAB repression domain.
  283. (2005). Lack of cross-species transmission of porcine endogenous retrovirus in pig-to-baboon xenotransplantation with sustained depletion of anti-alphagal antibodies.
  284. (2001). Lack of cross-species transmission of porcine endogenous retrovirus infection to nonhuman primate recipients of porcine cells, tissues, or organs.
  285. (2004). Late viral interference induced by transdominant Gag of an endogenous retrovirus.
  286. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.
  287. (1997). Leukemogenesis by Moloney murine leukemia virus: a multistep process.
  288. (1993). Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes.
  289. (1988). Lipid composition and fluidity of the human immunodeficiency virus.
  290. (2001). Long-term follow-up failed to detect in vitro transmission of full-length porcine endogenous retroviruses from specific pathogen-free pig islets to human cells.
  291. (2000). Long-term survival of nonhuman primates receiving life-supporting transgenic porcine kidney xenografts.
  292. (1974). Lower motor neuron degeneration associated with type C RNA virus infection in mice: neuropathological features.
  293. (2001). Mapping full-length porcine endogenous retroviruses in a large white pig.
  294. (2005). Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1,3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue.
  295. (2001). Mechanisms of viral membrane fusion and its inhibition.
  296. (2008). Mechanisms underlying glycosylation-mediated loss of ecotropic receptor function in murine MDTF cells and implications for receptor evolution.
  297. (2006). Mice transgenic for a human porcine endogenous retrovirus receptor are susceptible to productive viral infection.
  298. (2002). Microarray-based detection and genotyping of viral pathogens.
  299. (2002). Microchimerism and transmission of porcine endogenous retrovirus from a pig cell line or specific pathogen-free pig islets to mouse tissues and human cells during xenografts in nude mice.
  300. (1993). Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0).
  301. (2001). Modular organization of the Friend murine leukemia virus envelope protein underlies the mechanism of infection.
  302. (2008). Molecular characterization of unusual human G5P[6] rotaviruses identified in China.
  303. (1991). Molecular cloning and characterization of a novel human gene homologous to the murine ecotropic retroviral receptor.
  304. (1999). Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.
  305. (1995). Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth.
  306. (1995). Molecular cloning of a new interferoninduced factor that represses human immunodeficiency virus type 1 long terminal repeat expression.
  307. (1993). Molecular cloning of an apolipoprotein B messenger RNA editing protein.
  308. (1997). Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis.
  309. (2006). Molecular interactions between porcine and human gammaherpesviruses: implications for xenografts?
  310. (2005). Mouse mammary tumor virus encodes a self-regulatory RNA export protein and is a complex retrovirus.
  311. (2004). Mouse retrovirus mediates porcine endogenous retrovirus transmission into human cells in long-term human-porcine chimeric mice.
  312. (2006). Multiple genetic reassortment of avian and human influenza A viruses in European pigs, resulting in the emergence of an H1N2 virus of novel genotype.
  313. (2001). Multiple groups of novel retroviral genomes in pigs and related species.
  314. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo.
  315. (1985). Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon.
  316. (2006). Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms.
  317. (1997). Murine retroviruses use at least six different receptors for entry into Mus dunni cells.
  318. (2009). Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
  319. (1993). Mutation of amino acids within the gibbon ape leukemia virus (GALV) receptor differentially affects feline leukemia virus subgroup B, simian sarcoma-associated virus, and GALV infections.
  320. (1999). Mutation rates among RNA viruses.
  321. (1997). Mutational analysis of the proposed gibbon ape leukemia virus binding site in Pit1 suggests that other regions are important for infection.
  322. (1999). Mutations altering the moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle.
  323. (1990). Myristoylation-dependent replication and assembly of human immunodeficiency virus 1.
  324. (1986). Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.
  325. (2003). N-linked glycosylation and sequence changes in a critical negative control region of the ASCT1 and ASCT2 neutral amino acid transporters determine their retroviral receptor functions.
  326. (2007). Natural protection from zoonosis by alphagal epitopes on virus particles in xenotransmission.
  327. (1993). Naturally occurring antibodies devoid of light chains.
  328. (2009). Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists. Cell Host Microbe.
  329. (1989). Negative control region at the 5' end of murine leukemia virus long terminal repeats.
  330. (1988). Negative regulation of retrovirus expression in embryonal carcinoma cells mediated by an intragenic domain.
  331. (2004). New simian immunodeficiency virus infecting De Brazza's monkeys (Cercopithecus neglectus): evidence for a cercopithecus monkey virus clade.
  332. (2004). Nipah 231 virus encephalitis reemergence,
  333. (2005). Nipah virus in Lyle's flying foxes,
  334. (2003). Nipah virus outbreak in Malaysia.
  335. (2000). Nipah virus: a recently emergent deadly paramyxovirus.
  336. (2003). No evidence for productive PERV infection of baboon cells in in vivo infection model.
  337. (2000). No evidence of infection with porcine endogenous retrovirus in recipients of encapsulated porcine islet xenografts.
  338. (1998). No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts.
  339. (1998). No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys.
  340. (2009). No in vivo infection of triple immunosuppressed non-human primates after inoculation with high titers of porcine endogenous retroviruses.
  341. (1986). Noninflammatory spongiform polioencephalomyelopathy caused by a neurotropic temperaturesensitive mutant of Moloney murine leukemia virus TB.
  342. (1983). Nucleotide sequence of Rous sarcoma virus.
  343. (1988). Oligomeric structure of a prototype retrovirus glycoprotein.
  344. (1991). Oligomerization and transport of the envelope protein of Moloney murine leukemia virus-TB and of 234 ts1, a neurovirulent temperature-sensitive mutant of MoMuLV-TB.
  345. (2008). Oncogenesis by retroviruses: old and new paradigms.
  346. (1999). Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes.
  347. (2009). Origin, antiviral function and evidence for positive selection of the gammaretrovirus restriction gene Fv1 in the genus Mus.
  348. (1999). Outbreak of Nipahvirus infection among abattoir workers in Singapore.
  349. (2003). Packaging of human endogenous retrovirus sequences is undetectable in porcine endogenous retrovirus particles produced from human cells.
  350. (2007). Panmicrobial 252 oligonucleotide array for diagnosis of infectious diseases.
  351. (2002). PCR-based cloning and immunocytological titration of infectious porcine endogenous retrovirus subgroup A and B.
  352. (2005). Phosphatidylserine treatment relieves the block to retrovirus infection of cells expressing glycosylated virus receptors.
  353. (1971). Phospholipid composition of Rous sarcoma virus, host cell membranes and other enveloped RNA viruses.
  354. (2004). Phylogenetic relationship of porcine endogenous retrovirus (PERV) in Chinese pigs with some type C retroviruses.
  355. (2001). Physiological aspects of pig-to-primate renal xenotransplantation.
  356. (2001). Plasma membrane rafts play a critical role in HIV-1 assembly and release.
  357. (2000). PML 253 regulates p53 acetylation and premature senescence induced by oncogenic Ras.
  358. (1998). PML is essential for multiple apoptotic pathways.
  359. (2001). PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator.
  360. (1988). Point mutants of Moloney murine leukemia virus that fail to package viral RNA: evidence for specific RNA recognition by a "zinc finger-like" protein sequence.
  361. (1999). Polymerase chain reaction assays for the diagnosis of infection with the porcine endogenous retrovirus and the detection of pig cells in human and nonhuman recipients of pig xenografts.
  362. (2004). Porcine cell microchimerism but lack of productive porcine 237 endogenous retrovirus (PERV) infection in naive and humanized SCID-beige mice treated with porcine peripheral blood mononuclear cells.
  363. (2003). Porcine cytomegalovirus and coagulopathy in pig-to-primate xenotransplantation.
  364. (2008). Porcine endogenous retrovirus (PERV) and its transmission characteristics: a study of the New Zealand designated pathogen-free herd.
  365. (2006). Porcine endogenous retrovirus integration sites in the human genome: features in common with those of murine leukemia virus.
  366. (1999). Porcine endogenous retrovirus is transmitted neither in vivo nor in vitro from porcine endothelial cells to baboons.
  367. (2008). Porcine endogenous retrovirus transmission characteristics from a designated pathogen-free herd.
  368. (2002). Porcine endogenous retrovirus transmission characteristics of an inbred herd of miniature swine.
  369. (2003). Porcine endogenous retroviruses (PERVs) and xenotransplantation: screening for transmission in several clinical trials and in experimental models using non-human primates.
  370. (2001). Porcine endogenous retroviruses (PERVs): generation of specific antibodies, development of an immunoperoxidase assay (IPA) and inhibition by AZT.
  371. (2009). Porcine endogenous retroviruses PERV A and A/C recombinant are insensitive to a range of divergent mammalian TRIM5alpha proteins including human TRIM5alpha.
  372. (2005). Porcine endogenous retroviruses PERV-A and PERV-B infect neither mouse cells in vitro nor SCID mice in vivo.
  373. (2001). Porcine endogenous retroviruses: in vitro host range and attempts to establish small animal models.
  374. (1965). Porcine reproductive failure associated with a newly identified "SMEDI" group of picorna viruses.
  375. (2000). Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results.
  376. (1996). Positional cloning of the mouse retrovirus restriction gene Fv1.
  377. (2008). Positive selection and increased antiviral activity associated with the PARP-containing isoform of human zinc-finger antiviral protein.
  378. (2005). Possible risk factors for the transmission of hepatitis E virus and for the severe form of hepatitis E acquired locally in Hokkaido,
  379. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
  380. (2007). Pre-screening of miniature swine may reduce the risk of transmitting human tropic recombinant porcine endogenous retroviruses.
  381. (2001). Predicting transmembrane protein topology with a hidden Markov model: application to complete genomes.
  382. (2004). Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence.
  383. (2004). Prevalence of porcine endogenous retrovirus in domestic pigs in Japan and its potential infection in dogs xenotransplanted with porcine pancreatic islet cells.
  384. (2005). Prevention of PERV infections in pig to human xenotransplantation by the RNA interference silences gene.
  385. (2002). Production of alpha-1,3-galactosyltransferase knockout pigs by nuclear transfer cloning.
  386. (2004). Production of alpha-1,3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations.
  387. (2009). Production of transgenic pigs that express porcine endogenous retrovirus small interfering RNAs.
  388. (2006). Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.
  389. (2006). Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection.
  390. (1993). Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant,
  391. (2008). Pseudorabies virus infection in mink: a host-specific pathogenesis.
  392. (2005). Pseudotyping of porcine endogenous retrovirus by xenotropic murine leukemia virus in a pig islet xenotransplantation model.
  393. (2006). Quantitative membrane proteomics reveals new cellular targets of viral immune modulators.
  394. (2006). Rapid turnover and polyubiquitylation of the retroviral restriction factor TRIM5.
  395. (2005). Real-time reverse transcriptase PCR for the endogenous koala retrovirus reveals an association between plasma viral load and neoplastic disease in koalas.
  396. (2002). Reassessing the role of region A in Pit1-mediated viral entry.
  397. (1995). Receptor-binding domain of murine leukemia virus envelope glycoproteins.
  398. (2001). Receptors and entry cofactors for retroviruses include single and multiple transmembranespanning proteins as well as newly described glycophosphatidylinositolanchored and secreted proteins. Microbiol Mol Biol Rev 65, 371-389, table of contents.
  399. (1999). Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1.
  400. (1994). Reduced nuclear import of human immunodeficiency virus type 1 preintegration complexes in the presence of a prototypic nuclear targeting signal.
  401. (2004). Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.
  402. (2004). Reduction of 248 consumptive coagulopathy using porcine cytomegalovirus-free cardiac porcine grafts in pig-to-primate xenotransplantation.
  403. (2002). Relationship between SU subdomains that regulate the receptor-mediated transition from the native (fusion-inhibited) to the fusion-active conformation of the murine leukemia virus glycoprotein.
  404. (1964). Renal Heterotransplantation in Man.
  405. (1976). Reproductive disease experimentally induced by exposing pregnant gilts to porcine parvovirus.
  406. (1997). Requirements for different components of the host cell cytoskeleton distinguish ecotropic murine leukemia virus entry via endocytosis from entry via surface fusion.
  407. Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid.
  408. (1998). Resistance to virus infection conferred by the interferon-induced promyelocytic leukemia protein.
  409. (2006). Restriction of foamy viruses by APOBEC cytidine deaminases.
  410. (2002). Restriction of lentivirus in monkeys.
  411. (1997). Retrotransposons, Endogenous Retroviruses, and the Evolution of Retroelement.
  412. (2006). Retroviral invasion of the koala genome.
  413. (1997). Retroviral Pathogenesis.
  414. (1997). Retroviral virions and genomes.
  415. (2004). Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha.
  416. (1991). Retrovirus-induced feline pure red blood cell aplasia: pathogenesis and response to suramin.
  417. (1998). RING fingers and B-boxes: zinc-binding protein-protein interaction domains.
  418. (2000). RING for destruction?
  419. (2005). Rmcf2, a xenotropic provirus in the Asian mouse species Mus castaneus, blocks infection by polytropic mouse gammaretroviruses.
  420. (2001). RNA: guiding gene silencing.
  421. (2000). RNAi: doublestranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals.
  422. (1989). Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1.
  423. (2005). Role of lipid rafts in virus replication.
  424. (2008). Role of receptor polymorphism and glycosylation in syncytium induction and host range variation of ecotropic mouse gammaretroviruses.
  425. (1992). Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes.
  426. (2000). Rous sarcoma virus translation revisited: characterization of an internal ribosome entry segment in the 5' leader of the genomic RNA.
  427. (1999). Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue.
  428. (1996). Selective antibody reactivity with peptides from human endogenous retroviruses and nonviral poly(amino acids) in patients with systemic lupus erythematosus.
  429. (2007). Selective inhibition of porcine endogenous retrovirus replication in human cells by acyclic nucleoside phosphonates.
  430. (2001). Sensitive and specific immunological detection methods for porcine endogenous retroviruses applicable to experimental and clinical xenotransplantation.
  431. (1996). Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase.
  432. (1997). Sensitization of rhabdo-, lenti-, 266 and spumaviruses to human serum by galactosyl(alpha1-3)galactosylation.
  433. (2003). Serologic analysis of anti-porcine endogenous retroviruses immune responses in humans after ex vivo transgenic pig liver perfusion.
  434. (1985). Serologic identification and characterization of a macaque T-lymphotropic retrovirus closely related to HTLV-III.
  435. (1989). Severe immunodeficiency disease induced by a defective murine leukaemia virus.
  436. Simian AIDS: isolation of a type D retrovirus and transmission of the disease.
  437. (2009). Simian Immunodeficiency Virus envelope glycoprotein counteracts tetherin/BST2/CD317 by intracellular sequestration.
  438. (2005). Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1.
  439. (1996). Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resistance.
  440. (1998). Single amino acid insertion in loop 4 confers amphotropic murine leukemia virus receptor function upon murine Pit1.
  441. (2004). Single-strand specificity of 275 APOBEC3G accounts for minus-strand deamination of the HIV genome.
  442. (1987). Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer.
  443. (1988). Small finger protein of avian and murine retroviruses has nucleic acid annealing activity and positions the replication primer tRNA onto genomic RNA.
  444. (2000). Sodium-dependent neutral amino acid transporter type 1 is an auxiliary receptor for baboon endogenous retrovirus.
  445. (2009). Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.
  446. (1999). Species-specific, postentry barriers to primate immunodeficiency virus infection.
  447. (2005). Speciesspecific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction.
  448. (2006). Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.
  449. (1999). Specificities of multiple sclerosis cerebrospinal fluid and serum antibodies against mimotopes.
  450. (1981). Spongiform polioencephalomyelopathy caused by a murine retrovirus. II. Ultrastructural localization of virus replication and spongiform changes in the central nervous system.
  451. (2003). Sporadic acute or fulminant hepatitis E in
  452. (2003). Structure and mechanism of a coreceptor for infection by a pathogenic feline retrovirus.
  453. (2000). Study of full-length porcine endogenous retrovirus genomes with envelope gene polymorphism in a specific-pathogen-free Large White swine herd.
  454. (2000). Subcellular redistribution of Pit-2 P(i) transporter/amphotropic leukemia virus (A-MuLV) receptor in A-MuLV-infected NIH 3T3 fibroblasts: involvement in superinfection interference.
  455. (1996). Substitution of a single amino acid residue is sufficient to allow the human amphotropic murine leukemia virus receptor to also function as a gibbon ape leukemia virus receptor.
  456. (2002). Susceptibility of recombinant porcine endogenous retrovirus reverse transcriptase to nucleoside and non-nucleoside inhibitors.
  457. (2001). Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors.
  458. (1985). Susceptibility of wild mouse cells to exogenous infection with xenotropic leukemia viruses: control by a single dominant locus on chromosome 1.
  459. (2000). Syncytin is a captive retroviral envelope protein involved in human placental morphogenesis.
  460. (2005). Syncytin-A and syncytin-B, two fusogenic placenta-specific murine envelope genes of retroviral origin conserved in Muridae.
  461. (2009). Syncytin-A knockout mice demonstrate the critical role in placentation of a fusogenic, endogenous retrovirus-derived, envelope gene.
  462. (1997). Synthesis and Processing of viral RNA.
  463. (2002). Targeted disruption of the alpha1,3-galactosyltransferase gene in cloned pigs.
  464. (2008). Targeting dendritic cell signaling to regulate the response to immunization.
  465. (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
  466. Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.
  467. (2001). The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) in xenotransplantation.
  468. (1997). The amphotropic murine leukemia virus receptor gene encodes a 71-kilodalton protein that is induced by phosphate depletion.
  469. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
  470. (1996). The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
  471. (2006). The betaretrovirus Mason-Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles.
  472. (1994). The cellular receptor for gibbon ape leukemia virus is a novel high affinity sodium-dependent phosphate transporter.
  473. (1997). The critical N-linked glycan of murine leukemia virus envelope protein promotes both folding of the C-240 terminal domains of the precursor polyprotein and stability of the postcleavage envelope complex.
  474. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
  475. (2004). The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.
  476. (2006). The discovery of endogenous retroviruses.
  477. (1995). The dual-function hamster receptor for amphotropic murine leukemia virus (MuLV), 10A1 MuLV, and gibbon ape leukemia virus is a phosphate symporter.
  478. (2005). The effect of complement regulatory protein expression on pig endothelial cells to porcine endogenous retrovirus lyses by human sera.
  479. (2002). The envelope glycoprotein of human endogenous retrovirus type W uses a divergent family of amino acid transporters/cell surface receptors.
  480. (1996). The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?
  481. (1996). The expression of human endogenous retrovirus3 in fetal cardiac tissue and antibodies in congenital heart block.
  482. (2005). The highly structured encapsidation signal of MuLV RNA is involved in the nuclear export of its unspliced RNA.
  483. (2006). The HIV lipidome: a raft with an unusual composition.
  484. (1998). The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens.
  485. (2004). The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities.
  486. (1996). The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses.
  487. (2001). The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site.
  488. (1990). The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.
  489. (2006). The infectivity and host range of the ecotropic porcine endogenous retrovirus, PERV-C, is modulated by residues in the C-terminal region of its surface envelope protein.
  490. (2008). The interferoninduced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
  491. (2003). The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle.
  492. (1992). The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.
  493. (1994). The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.
  494. (2000). The nucleotide sequence of koala (Phascolarctos cinereus) retrovirus: a novel type C endogenous virus related to Gibbon ape leukemia virus.
  495. (1997). The origin and evolution of Ebola and Marburg viruses.
  496. The RD114/simian type D retrovirus receptor is a neutral amino acid transporter.
  497. (2007). The restriction of zoonotic PERV transmission by human APOBEC3G.
  498. (2001). The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E.
  499. (2003). The significance of N-linked glycosylation in pig endogenous retrovirus infectivity.
  500. (1987). The sor gene of HIV-1 is required for efficient virus transmission in vitro.
  501. (1995). The structural biology of type I viral membrane fusion.
  502. (2009). The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
  503. (2001). The tripartite motif family identifies cell compartments.
  504. (2003). The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
  505. (1994). The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells.
  506. (2004). The zinc finger antiviral protein directly binds to specific viral mRNAs through the CCCH zinc finger motifs.
  507. (2007). The zinc-finger antiviral protein recruits the RNA processing exosome to degrade the target mRNA.
  508. (1999). Three-month survival of HDAFF transgenic pig hearts transplanted into primates.
  509. (2003). Transcription start regions in the human genome are favored targets for MLV integration.
  510. (2008). Transgene Expression of Green Fluorescent Protein and Germ Line Transmission in Cloned Pigs Derived from In Vitro Transfected Adult Fibroblasts. Cloning Stem Cells.
  511. (1993). Transgenic Fv-4 mice resistant to Friend virus.
  512. (1990). Translational suppression in gene expression in retroviruses and retrotransposons.
  513. (1992). Translational suppression in retroviral gene expression.
  514. (2001). Transmembrane topology of PiT-2, a phosphate transporter-retrovirus receptor.
  515. (2000). Transmission of porcine endogenous retroviruses in severe combined immunodeficient mice xenotransplanted with fetal porcine pancreatic cells.
  516. (2005). Transplantation of micro- and macroencapsulated piglet islets into mice and monkeys.
  517. (2005). Transplantation of neonatal porcine islets and sertoli cells into nonimmunosuppressed nonhuman primates.
  518. Transplantation of porcine fetal pancreas to diabetic patients.
  519. (1991). Transport of cationic amino acids by the mouse ecotropic retrovirus receptor.
  520. (2004). Transport-deficient Pit2 phosphate transporters still modify cell surface oligomers structure in response to inorganic phosphate.
  521. (2007). Transspecies transmissions of retroviruses: new cases.
  522. (2007). TRIM28 mediates primer binding sitetargeted silencing of murine leukemia virus in embryonic cells.
  523. (2004). TRIM45, a novel human RBCC/TRIM protein, inhibits transcriptional activities of ElK-1 and AP-1.
  524. (2006). Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entry.
  525. (2004). TRIM5alpha mediates the postentry block to N-tropic murine leukemia viruses in human cells.
  526. (2004). Trim5alpha protein restricts both HIV-1 and murine leukemia virus.
  527. (2005). TRIM5alpha selectively binds a restriction-sensitive retroviral capsid.
  528. (1992). Tunicamycin treatment of CHO cells abrogates multiple blocks to retrovirus infection, one of which is due to a secreted inhibitor.
  529. (1989). Two blocks in Moloney murine leukemia virus expression in undifferentiated F9 embryonal carcinoma cells as determined by transient expression assays.
  530. (1997). Two sets of human-tropic pig retrovirus.
  531. (1998). Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells.
  532. (2003). Ultra-sensitive and specific detection of porcine endogenous retrovirus (PERV) using a sequence-capture real-time PCR approach.
  533. (2005). Use of different but overlapping determinants in a retrovirus receptor accounts for non-reciprocal interference between xenotropic and polytropic murine leukemia viruses.
  534. (1975). Use of porcine skin in burn treatment.
  535. (2007). Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up.
  536. (1997). Variable regions A and B in the envelope glycoproteins of feline leukemia virus subgroup B and amphotropic murine leukemia virus interact with discrete receptor domains.
  537. (2004). Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.
  538. (2003). Viral discovery and sequence recovery using DNA microarrays.
  539. (1997). Viral Entry and Receptors.
  540. (2003). Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.
  541. (1977). Virus infection of murine teratocarcinoma stem cell lines.
  542. (1994). Virus receptors: binding, adhesion strengthening, and changes in viral structure.
  543. (2009). Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
  544. (2009). Vpu Directs the Degradation of the HIV Restriction Factor BST-2/tetherin via a {beta}TrCP-dependent Mechanism.
  545. (2007). West Nile virus.
  546. (2003). Xenoreactive anti-Galalpha(1,3)Gal antibodies prevent porcine endogenous retrovirus infection of human in vivo.
  547. (2002). Xenotransplantation for liver therapy or: Can porcine hepatocytes generate physiological functions sufficient for a human patient in ALF?
  548. (2009). Xenotransplantation of solid organs in the pig-to-primate model.
  549. (2007). Xenotransplantation: current status and a perspective on the future.
  550. (1997). Yersinia pestis--etiologic agent of plague.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.